Smoking Doubles MOGAD Relapses — Quitting Helps

Credibility

Interest

Key Takeaway

Current smokers with MOG antibody disease (MOGAD) had about double the relapse rate, so quitting smoking may lower flare-ups.

What They Found

Researchers looked at 172 people with MOGAD and compared who smoked, used to smoke, or never smoked, and checked for common blood vessel problems (like high blood pressure, high cholesterol, diabetes, or high body weight). They found current smokers had about 2.2 times more relapses than people who never smoked, meaning more flare-ups over time. People who used to smoke did not have more relapses than never-smokers, suggesting the extra risk goes away after quitting. The time until a person moved from single attack to repeated attacks tended to be shorter in current smokers, but that link was not strong enough after adjusting for other factors. Having vascular risk factors (high blood pressure, cholesterol, diabetes, or high body mass index) did not change relapse rates or time-to-relapse in this study.

Who Should Care and Why

People with MOGAD and their caregivers should care because relapses can cause new or worse symptoms and may affect long-term recovery — so anything that lowers relapse risk matters. The finding is most relevant to current smokers with MOGAD: think of smoking as adding fuel to a small fire of inflammation in the nervous system. Past smokers did not show the higher relapse rate, so quitting smoking may reduce that extra risk over time, like removing fuel from the fire. Healthcare providers who treat MOGAD should discuss smoking cessation as part of care planning, much like advising to stop smoking to protect the heart or lungs. Caregivers can support quitting efforts (help find programs, remind about appointments, encourage healthy routines) because stopping smoking may help reduce future relapses.

Important Considerations

This study looked at patients from one specialist center and included 172 people, so results may not be exactly the same for every group of patients. The study shows an association (link) between current smoking and more relapses, but it cannot prove smoking directly causes the relapses. The lack of effect for vascular risk factors might be because of how common or well-controlled those conditions were in this group, so other studies could find different results.

AI-generated summary — for informational purposes only, not medical advice

Categories:

MS Progression Specific Symptoms Living with MS

Article Topics:

MOGADMyelin oligodendrocyte glycoprotein antibody-associated diseaserelapsesmokingvascular risk factors

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Multiple sclerosis (Houndmills, Basingstoke, England) often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News